Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

PRE Commercial Aims to Boost Life Science Commercial Readiness


BOSTON, Sept. 14, 2021 /PRNewswire/ -- PRE Commercial, a life science marketing consulting and insights company, opened its doors this week with the commitment to help biotech and pharmaceutical teams get product launch ready?faster, more efficiently, and more effectively. The organization, built by two industry veterans, aims to fill an unmet need in the life science space providing a dedicated, experienced commercial partner to executives and marketing leaders running clinical-stage pipelines.

"Leaders in early-stage biopharma are understandably hyper-focused on clinical and regulatory milestones. In our experience, the most successful organizations also incorporate commercial thinking earlier in the development cycle shaping their market environment, pre-positioning their therapeutics, and clearly defining a corporate identity. With the right insights and planning these organizations are better prepared to get their groundbreaking therapies in to the hands of patients and build the value of their enterprise," said Maureen Franco, CEO of PRE Commercial.

And there is a need. The most critical time to prepare for a pharmaceutical launch is well before regulatory approval. Several recent studies have shown significant gaps in achieving launch expectations including a 2020 PharmaExec.com study showing almost 50% of first commercial biotech organizations significantly missed first-year launch revenue compared to forecast.

"We've launched multiple pharmaceutical brands over the years. Companies that commit to building an early foundation find greater success at launch. Our methodology includes understanding and shaping the disease environment prelaunch, and working to develop product and corporate brand rationale within the competitive framework. We've also developed a product to help early stage biopharma better understand key customers by tracking changes in their sentiment over time," said Mike Hodgson, CSO of PRE Commercial.

PRE's founders were partners at Cambridge BioMarketing (CB), the leading marketing agency focused on companies developing life-saving therapeutics for patients with rare diseases. Maureen Franco served as CEO of CB and led the agency's growth and eventual sale to UDG Healthcare. She brings +25 years of commercial life science leadership experience including over a decade at Sanofi Genzyme in commercial executive roles. Mike Hodgson served as CCO at CB and as one of the early partners, directed the strategic launch of dozens of orphan brands. He brings +25 years in life science communications strategy with an emphasis on creative content and positioning strategy, corporate branding, and disease shaping approaches.

About PRE Commercial
PRE Commercial is a marketing consulting company solely dedicated to early-stage life science companies. With a combination of deep industry expertise and key customer insights, the organization provides life science commercial executives with a partnership to build enterprise value in their precommercial environment. Across therapeutic categories, PRE advises start-up to multinational life science organizations preparing for product launch. With headquarters in Boston, MA the team is passionately committed to helping life science organizations prepare and achieve commercial success.

Media Contact:
Maureen Franco
[email protected] 
617-412-5430

SOURCE PRE Commercial


These press releases may also interest you

at 16:05
Data I/O Corporation , the leading global provider of advanced security and data deployment solutions for microcontrollers, security ICs and memory devices, today announced financial results for the first quarter ended March 31, 2024. First Quarter...

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...

at 16:05
Bruker Corporation today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current...

at 16:05
Gilead Sciences, Inc. announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and...

at 16:05
Doximity, Inc. , the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2024 after market close on May 16, 2024. Doximity will host a...



News published on and distributed by: